Shaping tomorrow’s cancer therapies

SATMEG Ventures is developing new treatments for solid tumours. The company commercialises research results from the Sahlgrenska Translational Melanoma Group (SATMEG) to provide tailored therapies for melanoma patients.

Impact: Transform advanced cancer research into personalised therapies.

Founder and Chairman: Jonas Nilsson

GUV Contact: Lorna Fletcher